Pterostilbene · Pterostilbene
Resveratrol's more bioavailable cousin, mostly used in blends.
Short answer
Pterostilbene (Pterostilbene) is a polyphenol / sirtuin activator with evidence grade D, meaning it is primarily supported by animal studies. We track 8 produkter containing Pterostilbene. Typical doses range from 12.0 to 100.0 mg per portion. The top-ranked product scores 6.1 out of 10 on our composite scale (dose, evidence, price, testing, transparency). Prices range up to $129.00 per månad.
Top Pterostilbene produkter
| Product | Varumärke | Dose | Pris/mo | 3rd-party tested | Poäng |
|---|---|---|---|---|---|
| NOVOS Core | 50 mg | $89.00 | Yes | 6.1 | |
| Basis | 50 mg | $60.00 | Yes | 6.1 | |
| Daily Ultimate Essentials | 25 mg | $129.00 | Yes | 6.0 | |
| Pterostilbene Supplement | 100.0 mg | $19.95 | Yes | 5.8 | |
| Optimized Resveratrol Elite | 20 mg | $40.00 | Yes | 5.6 |
Scores are editorial judgments, not a scientific standard. Se how we score.
What it is
A close relative of resveratrol found in blueberries and Indian sandalwood. The chemical tweaks make it about 4× better absorbed than resveratrol.
Why people take it
Small human trials suggest cholesterol effects at high doses. Longevity data is animal-only. Often paired with NR in NAD+ formulas because of a putative synergy.
Our verdict
Reasonable stacking ingredient with NR; not a standalone longevity therapy.
Structure & class
3,5-dimethoxy-4'-hydroxy-trans-stilbene. Higher lipophilicity and bioavailability than resveratrol due to methoxy substitution.
Mechanism & clinical data
Bioavailability ~80% vs <1% for resveratrol. Riche et al. 2013 showed LDL increase at 250 mg/day, cautioning against high-dose monotherapy. Common in NR+PT stacks marketed for NAD+ support.
Pharmacokinetics
~105 min (2× longer than resveratrol).
Dose & forms
What to watch out for
High-dose pterostilbene can raise LDL. Keep to <150 mg/day unless working with a clinician.
Where this dose comes from
The trial dose above is our editorial pick from the published human trials for this ingredient. We choose the dose that the best-available studies used on the endpoint most relevant to longevity. The range shows the lowest and highest doses tested in published trials. The landmark studies below are the papers we read to set it. You can click through and check our work.
When new trials publish, our automated sweeps flag them. If a new study materially changes the dose, we update it through editorial review and record the old dose, new dose, and the triggering study in every affected product's recommendation history. The dose is never changed automatically.
Regelverk status
Timeline
Regelverk events, evidence grade changes, and key research milestones for Pterostilbene, most recent first. Every entry links to its primär source.
-
EU Court sharpens the bar for botanical health claimsA Court of Justice of the European Union ruling in april 2025 further tightened the requirements for how botanical ingredients (herbs, plant extracts) can be marketed with health claims in the EU, effectively removing much of the flexibility of the on-hold list.
-
EU report identifies 117 supplement substances as potential health risksThe HoA Working Group on Food Supplements (26 European countries) published its first report evaluating 117 substances used in food supplements. Of these, 65 were assessed as likely novel foods, 6 were already regulated, 34 had insufficient data, and 12 were prioritized for Article 8 restriction under Regulation (EC) No 1925/2006. The 12 priority substances include ashwagandha, curcumin, melatonin, piperine, St. John's wort, coumarin, p-synephrine, maca, holy basil, Melaleuca, black cohosh, and L-tryptophan. The report drew on 1,500 RASFF alerts reviewed between 2017 and mid-2022.
-
EU Health Claims Regulation adoptedRegulation (EC) No 1924/2006 laid down harmonised rules for nutrition and health claims made on foods, including supplements. Only claims listed in the EU Register of authorised claims can be used. Rejected botanical claims are held in a separate on-hold list.
-
EU introduces the Novel Food RegulationRegulation (EC) No 258/97 required any food or food ingredient without a history of consumption in the EU before 15 maj 1997 to be authorised before being placed on the market. This is the framework that captures NMN, spermidine as a supplement ingredient, urolithin A, and many other longevity actives.
The only substantial human RCT of pterostilbene found it raised LDL cholesterol at both doses tested while lowering blood pressure, a mixed result marketers rarely mention.
Verified 2026-07-23. We update this section as new peer-reviewed trials land.
Best-supported claim
Pterostilbene's clearest human effect is on blood pressure, not cholesterol. Riche et al.'s randomized, dubbelblind, placebokontrollerad trial in 80 adults with hypercholesterolemia found 250 mg/day of pterostilbene for 6-8 weeks significantly lowered systolic blood pressure by 7.8 mmHg and diastolic blood pressure by 7.3 mmHg versus placebo (https://pmc.ncbi.nlm.nih.gov/articles/PMC4099343/). The same trial's companion safety analysis found no adverse effects on liver, kidney, or glucose markers at doses up to 250 mg/day, establishing tolerability even though the efficacy picture was mixed (https://onlinelibrary.wiley.com/doi/10.1155/2013/463595).
Not supported by the evidence base
Pterostilbene is marketed as a more bioavailable, longevity-boosting cousin of resveratrol that improves cardiovascular and metabolic health, but the only sizable human RCT found pterostilbene monotherapy significantly increased LDL cholesterol by about 17 mg/dL, the opposite of what a heart-health supplement should do (https://pmc.ncbi.nlm.nih.gov/articles/PMC4099343/). Marketing also leans on animal data showing pterostilbene protects against diabetic cognitive impairment through gut-brain axis mechanisms and against Alzheimer's-related neurodegeneration, but this evidence comes largely from rodent models and cell studies, not human trials, and no published human cognitive RCT of pterostilbene exists as of 2026 (https://pubmed.ncbi.nlm.nih.gov/37037513/, https://pmc.ncbi.nlm.nih.gov/articles/PMC12032911/).
Typical dose
100-250 mg/day, the only doses tested in human RCTs
Säkerhet
Pterostilbene was well tolerated up to 250 mg/day for 6-8 weeks in the only major human RCT, with no adverse drug reactions on liver, kidney, or glucose markers and no significant self-reported adverse events (https://onlinelibrary.wiley.com/doi/10.1155/2013/463595). The same trial found high-dose pterostilbene lowered HDL cholesterol by about 5 mg/dL in a subgroup not taking cholesterol medication, a potential downside for heart health. Because pterostilbene monotherapy raised LDL cholesterol in this trial, people with existing high cholesterol or cardiovascular risk should be cautious and discuss use with a physician before supplementing (https://pmc.ncbi.nlm.nih.gov/articles/PMC4099343/).
Interactions worth flagging
- maj have additive blood-pressure-lowering effects with antihypertensive medications
- Could raise LDL cholesterol, relevant for people on statins or other lipid-lowering therapy who should monitor lipid panels
Three recent studies to know
-
Pterostilbene could alleviate diabetic cognitive impairment by suppressing TLR4/NF-κB pathway through microbiota-gut-brain axis
In diabetic mice, pterostilbene improved cognitive dysfunction and reduced neuroinflammation via gut-brain axis mechanisms, but this has not been tested in human trials.
Läs studie → -
Pterostilbene: A natural neuroprotective stilbene with anti-Alzheimer's disease properties
Systematic review of preclinical studies finds pterostilbene shows neuroprotective and anti-Alzheimer's properties in animal and cell models, but human clinical trial data for neurological outcomes remain absent.
Läs studie → -
Unlocking the therapeutic potential of natural stilbene: Exploring pterostilbene as a powerful ally against aging and cognitive decline
Review of pterostilbene's proposed anti-aging mechanisms notes the human evidence base is limited mainly to the single metabolic-parameters RCT from 2014.
Läs studie →
Landmark studies
-
Riche et al. 2013
12 weeks of 250 mg/day lowered blood pressure but raised LDL.
Läs studie →
Found in these produkter (8)
Alla produkter in our catalog that contain Pterostilbene, ranked by our overall score. Ranking is editorial, never paid.
Buying guides and comparisons
Related ingredients
Se alla in Polyphenol / Sirtuin activator →Molekyler in the same class, plus the actives most often formulated alongside Pterostilbene in our catalogue.
Frequently asked questions
What is Pterostilbene?
A close relative of resveratrol found in blueberries and Indian sandalwood. The chemical tweaks make it about 4× better absorbed than resveratrol.
What dose of Pterostilbene should I take?
The trial dose in published human studies is 100 mg per dag, with a range of 50 to 250 mg per dag. Always consult a qualified clinician before starting any supplement.
Is Pterostilbene safe?
High-dose pterostilbene can raise LDL. Keep to <150 mg/day unless working with a clinician.
What is the best Pterostilbene supplement?
We track 8 produkter containing Pterostilbene. The top-ranked product scores 6.1 out of 10 on our composite scale, which evaluates dose, evidence, price, third-party testing, and transparency. See the comparison table above. Scores are editorial judgments, not a scientific standard.
What is the evidence grade for Pterostilbene?
Pterostilbene has evidence grade D, meaning it is primarily supported by animal studies. Grade A means replicated human RCTs with hard endpoints. Grade B means human RCTs with biomarker outcomes. Grade C means mixed or small human trials. See our evidence grading methodology.
Data verification
Bevisning grades are reviewed when new human RCTs are published. Product counts update automatically as new produkter are added. Dose ranges reflect published trial data, not brand recommendations. Read how we verify.